<DOC>
	<DOCNO>NCT00174616</DOCNO>
	<brief_summary>Primary objective : - Pathological complete response ( ypT0N0 ) rate Secondary objective : - Histopathological R0 resection rate - Pathological downstaging ( ypT0-T2N0 ) rate - One month surgical complication rate - Predictive value pre-operative MRI surgical , pathological clinical outcome - Safety - Local distant recurrence rate - Progression-free survival - Overall survival</brief_summary>
	<brief_title>CORE : Capecitabine , Oxaliplatin , Radiotherapy Excision</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proven adenocarcinoma rectum ( Tumour ≤ 12 cm anal verge ) No evidence distant spread No prior therapy chemotherapy radiation therapy rectal cancer Patient consider locally advanced MRI : Tumour beyond mesorectal fascia , Tumour ≤ 2mm mesorectal fascia , T3 tumour &lt; 5cm anal verge For female patient childbearing potential , neither pregnant breastfeeding , active contraception No peripheral neuropathy &gt; grade1 ECOG PS ≤ 2 ANC &gt; 1,500 x 10^9/L Platelets &gt; 100,000 x 10^9/L Creatinine &lt; 1.5 x IULN Bilirubin &lt; 1.5 IULN SGPT ( ALT ) &lt; 2.5 IULN No preexist condition would deter chemoradiotherapy No uncontrolled diarrhoea fecal incontinence No significant small bowel ( &gt; 200cc 6X6X6cm ) delineate within radiation field No serious uncontrolled concomitant illness Informed consent sign The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>